, Les traitements possibles en fonction de l'étendue du lymphome au moment du diagnostic -Les traitements, en chiffres | Fondation ARC pour la recherche sur le cancer, 2019.

S. Zhang, X. Liu, and T. Bawa-khalfe, Identification of the molecular basis of doxorubicin-induced cardiotoxicity, Nat Med, vol.18, issue.11, pp.1639-1681, 2012.

K. M. Tewey, T. C. Rowe, L. Yang, B. D. Halligan, and L. F. Liu, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II, Science, vol.226, issue.4673, pp.466-474, 1984.

. Anthracycline,

. Wikipédia, , 2017.

Y. Ichikawa, M. Ghanefar, and M. Bayeva, Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation, J Clin Invest, vol.124, issue.2, pp.617-647, 2014.

M. Lotrionte, G. Biondi-zoccai, and A. Abbate, Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity, Am J Cardiol, vol.112, issue.12, pp.1980-1984, 2013.

K. Dickstein, A. Cohen-solal, and G. Filippatos, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Eur J Heart Fail, vol.10, issue.10, pp.933-89, 2008.

J. L. Zamorano, P. Lancellotti, R. Muñoz, and D. , ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the, European Society of Cardiology, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01788726

, Eur J Heart Fail, vol.19, issue.1, pp.9-42, 2017.

X. Troussard, V. Duchenet, E. Cornet, D. Mouchel, M. Malet et al., , 1997.

, Rev Epidemiol Sante Publique, vol.57, issue.3, pp.151-159, 2009.

J. C. Plana, M. Galderisi, and A. Barac, Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, vol.15, issue.10, pp.3555-62, 2013.

H. Abdel-qadir, G. Ong, and R. Fazelzad, Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis, Ann Oncol Off J Eur Soc Med Oncol, vol.28, issue.3, pp.628-661, 2017.

M. S. Avila, S. M. Ayub-ferreira, and M. R. De-barros-wanderley, Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial, J Am Coll Cardiol, vol.71, issue.20, pp.2281-90, 2018.

P. Shah, R. Garris, and R. Abboud, Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy

, Am J Cardiol, 2019.

D. M. Gujral, G. Lloyd, and S. Bhattacharyya, Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab, Breast Edinb Scotl, vol.37, pp.64-71, 2018.

S. L. Heck, G. Gulati, and P. Hoffmann, Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial, Eur Heart J Cardiovasc Imaging, vol.19, issue.5, pp.544-52, 2018.

Z. Wang, Q. Niu, and X. Peng, Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR, Int J Cardiol, vol.214, pp.348-57, 2016.

H. Sawaya, I. A. Sebag, and J. C. Plana, Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab, Circ Cardiovasc Imaging, vol.5, issue.5, pp.596-603, 2012.

P. Thavendiranathan, F. Poulin, K. Lim, J. C. Plana, A. Woo et al., Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review, J Am Coll Cardiol, vol.63, pp.2751-68, 2014.

A. Saikhan, L. Park, C. Hardy, R. Hughes, and A. , Prognostic implications of left ventricular strain by speckle-tracking echocardiography in the general population: a meta-analysis, vol.15, pp.229-51, 2019.

L. Jovenaux, J. Cautela, and N. Resseguier, Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey, Int J Cardiol, vol.241, pp.387-92, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01798104

P. O'brien, K. Matheson, A. Jeyakumar, K. Anderson, and T. Younis, The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis, Breast Cancer Res Treat, vol.174, issue.2, pp.357-63, 2019.

D. Cardinale, G. Biasillo, M. Salvatici, M. T. Sandri, and C. M. Cipolla, Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy, Expert Rev Mol Diagn, vol.17, issue.3, pp.245-56, 2017.

, « Par délibération de son Conseil en date du 10 Novembre, 1972.

L. Vu, V. U. Président-de-thèse, . Le-doyen-de-la-faculté, and . Vu,

D. Impact and . Retrospective,

R. De, L. A. These, and . Français, BB) et des inhibiteurs de l'enzyme de conversion (IEC) sur la survenue d'une cardiopathie aux anthracyclines (ATC) chez des patients hypertendus atteints de lymphome reste mal connu à ce jour. Matériels et Méthodes Nous avons extrait les patients hypertendus atteints de lymphome Hodgkinien (LH) ou non Hodgkinien (LNH) du registre régional basnormand d'hématologie, et recueilli leurs données grâce au logiciel médical « Crossway » du CHU de Caen. La survenue d'une dysfonction ventriculaire gauche (DVG) était définie par une altération de la fraction d'éjection ventriculaire gauche (FEVG) définie soit par une FEVG<50% chez un patient avec une FEVG normale initialement, soit une baisse de 10% par rapport à la FEVG initiale mesurée en préchimiothérapie. L'objectif principal était la recherche d'un rôle protecteur d, Introduction L'amélioration du pronostic global des patients atteints d'un cancer entraine de nouvelles problématiques quant aux effets indésirables en lien avec leur chimiothérapie. L'impact des bétabloquants

, Sur les 93 patients, 35 ont développé une DVG, soit 37.6%. Quarante et un patients prenaient des IEC (44.1%), 51 patients des BB (54.8%) et 22 (23.7%) des BB et des IEC. Il n'y avait pas de différence statistiquement significative entre les 2 groupes (DVG et non DVG), Résultats Parmi ces 1324 patients atteints d'un lymphome, nous avons identifié 93 patients hypertendus traités, ayant reçu des ATC et disposant de FEVG pré et post-chimiothérapie

, Parmi les patients atteints de LH ou LNH, hypertendus traités et ayant reçu des ATC

. Mots-cles-;-/-fevg, . Impact, . Betablockers, . Angiotensin, . Enzyme et al., Introduction Improvement in the prognosis of cancer patients has led to new concerns about anticancer drugs side effects. Whether betablockers (BB) and angiotensin converting enzyme inhibitors (ACE-I) could prevent the anthracycline's (ATC) cardiotoxicity in patients with lymphoma

, Left ventricle dysfunction (LVD) occurrence was defined by a degradation of the left ventricular ejection fraction (LVEF), either by a LVEF<50% or a degradation of 10% comparatively to the previous LVEF before the chemotherapy. The principal objective was to evaluate the impact of BB and/or ACE-I on LVD development associated to ATC, Results Among the 1324 patients with LH or LNH, we included 93 patients treated for HBP and having received ATC and with available LVEF

, Forty one patients had an ACE-I (44.1%), 51 patients a BB (54.8%) and 22 patients an ACE-I and a BB (23.7%). There was no significant difference between the two groups (LVD and no LVD) regarding BB (p=0.40), ACE-I, Thirty-five patients developed a DVG (37.6%)

, Conclusion Among lymphoma patients treated for HBP and having received ATC, BB and ACE-I do not seem to have any protective effect on LVD development

. Key-words, Lymphoma/ Anthracycline/ Betablocker/ Angiotensin converting enzyme inhibitors/ Left ventricular ejection fraction